| Literature DB >> 25732200 |
Yok-Ai Que1, Virginie Virgini, Elise Dupuis Lozeron, Géraldine Paratte, Guy Prod'hom, Jean-Pierre Revelly, Jean-Luc Pagani, Emmanuel Charbonney, Philippe Eggimann.
Abstract
PURPOSE: To identify risk factors associated with mortality in patients with severe community-acquired pneumonia (CAP) caused by S. pneumoniae who require intensive care unit (ICU) management, and to assess the prognostic values of these risk factors at the time of admission.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25732200 PMCID: PMC7101553 DOI: 10.1007/s15010-015-0755-0
Source DB: PubMed Journal: Infection ISSN: 0300-8126 Impact factor: 3.553
Characteristics of the patients with severe pneumonia caused by S. pneumoniae
| All patients ( | Alive ( | Dead ( |
| |
|---|---|---|---|---|
| Demographics | ||||
| Age (years), mean (SD) | 55.7 (16.8) | 54.7 (16.8) | 61.2 (16.2) | NS |
| >65 years, | 27 (35.1) | 21 (32.3) | 6 (50) | NS |
| Male gender, | 56 (72.2) | 46 (70.7) | 10 (83.3) | NS |
| Underlying conditions | ||||
| Cardiovascular disease, | 50 (64.9) | 42 (64.6) | 8 (66.6) | NS |
| Ischemic heart disease, | 16 (20.8) | 12 (18.5) | 4 (33.3) | NS |
| Valvular heart disease, | 2 (2.6) | 2 (3.1) | 0 (0) | NS |
| Heart failure, | 5 (6.5) | 4 (6.2) | 1 (8.3) | NS |
| Arrhythmia, | 10 (13) | 9 (13.8) | 1 (8.3) | NS |
| HTA | 24 (31.2) | 20 (30.8) | 4 (33.3) | NS |
| COPD, | 14 (18.2) | 13 (20) | 1 (8.3) | NS |
| Sleep apnea syndrome, | 4 (5.2) | 4 (6.2) | 0 (0) | NS |
| Liver disease, | 23 (29.9) | 17 (26.2) | 6 (50) | NS |
| Cirrhosis, | 9 (11.7) | 6 (9.2) | 3 (25) | NS |
| Hepatitis, | 12 (15.5) | 10 | 2 (16.7) | NS |
| Renal disease, | 9 (11.7) | 8 (12.3) | 1 (8.3) | NS |
| Neurological disease, | 20 (26) | 16 (24.6) | 4 (33.3) | NS |
| Epilepsy | 6 (7.8) | 6 (9.2) | 0 (0) | NS |
| Stroke | 5 (6.5) | 3 (4.6) | 2 (16.7) | NS |
| Cancer, | 16 (20.8) | 12 (18.5) | 4 (33.3) | NS |
| HIV, | 9 (11.7) | 7 (10.8) | 2 (16.7) | NS |
| Substance abuse, | 24 (31.2) | 18 (27.7) | 6 (50) | NS |
| Splenectomy, | 3 (3.9) | 2 (3.1) | 1 (8.3) | NS |
| Initial antibiotic treatment, | ||||
| Combined treatment | 56 (72.3) | 45 (69.2) | 11 (91.7) | NS |
| Betalactam and macrolide | 43 (55.8) | 34 (52.3) | 9 (75) | NS |
| Betalactam and carbapenem | 6 (7.8) | 5 (7.7) | 1 (8.3) | NS |
| Betalactam and glycopeptide | 1 (1.3) | 1 (1.5) | 0 (0) | NS |
| Carbapenem and glycopeptide | 5 (6.5) | 4 (6.2) | 1 (8.3) | NS |
| Glycopeptide and macrolide | 1 (1.3) | 1 (1.5) | 0 (0) | NS |
| Monotherapy | 21 (27.3) | 20 (30.7) | 1 (8.3) | NS |
| Carbapenem monotherapy | 1 (1.3) | 1 (1.5) | 0 (0) | NS |
| Betalactam monotherapy | 20 (26) | 19 (29.2) | 1 (8.3) | NS |
| Risk factors for | ||||
| Past pneumococcal infection, | 2 (2.6) | 2 (3.1) | 0 (0) | NS |
| Active smoker, | 25 (32.5) | 21 (32.3) | 4 (33.3) | NS |
| Obesity (BMI > 30 kg/m2), | 6 (7.8) | 6 (9.2) | 0 (0) | NS |
| BMI, mean (SD) | 24.7 (5.1) | 24.1 (4.3) | 24.8 (5.3) | NS |
COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, BMI body mass index, NS not significant (dead vs alive)
* Fisher’s exact test or student’s t test (alive vs dead)
Severity of the infection and the supportive measures required to treat the patients
| All patients ( | Alive ( | Dead ( |
| |
|---|---|---|---|---|
| Sepsis, | 22 (28.6) | 20 (30.8) | 2 (16.7) | NS |
| Severe sepsis, | 20 (26) | 19 (29.2) | 1 (8.3) | NS |
| Septic shock, | 34 (44.2) | 25 (38.5) | 9 (75) | 0.03 |
| Severity scores | ||||
| APACHE II, median (IQR) | 19 (13) | 18 (13) | 28.5 (11) | 0.004 |
| SAPS II, median (IQR) | 47 (20) | 42 (26) | 59.5 (10) | 0.002 |
| Organ dysfunctions | ||||
| SOFA at 24 h, median (IQR) | 8 (5) | 8 (4) | 13 (3) | <0.0001 |
| MOF, | 14 (18.2) | 8 (12.3) | 6 (50) | 0.006 |
| Acute renal failurea, | 31 (44.3) | 25 (41.7) | 6 (60) | NS |
| DICa, | 7 (10) | 4 (6.7) | 3 (30) | 0.055 |
| Respiratory failure | ||||
| ARDSa, | 3 (4.3) | 2 (33.3) | 1 (10) | NS |
| NIV, | 46 (59.7) | 43 (66.2) | 3 (25) | 0.01 |
| NIV failure, | 21 (27.3) | 18 (27.7) | 3 (25) | NS |
| Invasive ventilation, | 58 (75.3) | 47 (72.3) | 11 (91.7) | NS |
| Duration of MV (days), median (IQR) | 3 (8) | 2 (8) | 5.5 (11) | NS |
| ICU LOS (days), median (min–max) | 8.6 (1–39) | 8.6 (9) | 8.5 (6.5) | NS |
| Microbiological documentation | ||||
| Positive sputum, | 25 (32.5) | 20 (30.8) | 5 (41.7) | NS |
| Positive blood culture, | 42 (54.5) | 34 (52.3) | 8 (66.7) | NS |
| Positive urinary antigen, | 44 (57.1) | 40 (61.5) | 4 (33.3) | NS |
| Biological values at admission | ||||
| Leucocytes (g/L), mean (SD) | 13.4 (9.5) | 13.7 (9.5) | 11.7 (9.8) | NS |
| Band forms, | 34 (44.2) | 26 (0.4) | 8 (66.7) | NS |
| CRP (mg/L), mean (SD) | 237 (140) | 253 (137) | 151 (128) | 0.02 |
ARDS Adult respiratory distress syndrome, MOF Multiple organ dysfunction (>3), DIC disseminated intra-vascular coagulation, NIV non-invasive ventilation, MV mechanical ventilation, ICU LOS ICU length of stay, NS not significant (dead vs alive)
Fisher’s exact test or student’s t test or Mann–Whitney U test
aFor 70 patients (60 alive and 10 dead)
Fig. 1CRP levels among patients with fatal outcomes. Proportion of patients who died according to terciles of CRP levels. Two-thirds of the patients who died (8 of 12) presented with a CRP level below 158 mg/L. Of these eight patients, three quarters (6 of 8) had a CRP value below 133 mg/L
Characteristics of the patients according to CRP terciles
| CRP < 158 ( | CRP = 159–302 ( | CRP > 302 ( |
| |
|---|---|---|---|---|
| Mortality, | 8 (30.8) | 2 (8) | 2 (7.7) | 0.032 |
| Demographics | ||||
| Age (years), mean (SD) | 57.4 (16) | 52.4 (15.4) | 57.4 (18.8) | NS |
| >65 years, | 9 (34.6) | 6 (24) | 12 (46.2) | NS |
| Male gender, | 18 (69.2) | 20 (80) | 18 (69.2) | NS |
| Underlying conditions | ||||
| Cardiovascular disease, | 18 (69.2) | 15 (60) | 17 (65.4) | NS |
| COPD, | 6 (23.1) | 6 (24) | 2 (7.7) | NS |
| Liver disease, | 10 (38.3) | 8 (32) | 5 (19.2) | NS |
| Renal disease, | 4 (15.4) | 2 (8) | 3 (11.5) | NS |
| Neurological disease, | 6 (23.1) | 8 (32) | 6 (23.1) | NS |
| Cancer, | 5 (19.2) | 6 (24) | 5 (19.2) | NS |
| HIV, | 2 (7.7) | 5 (20) | 2 (7.7) | NS |
| Substance abuse, | 9 (34.6) | 9 (36) | 6 (23.1) | NS |
| Splenectomy, | 2 (7.7) | 0 (0) | 1 (3.8) | NS |
| Risk factors for | ||||
| Past pneumococcal infection, | 1 (3.8) | 1 (4) | 0 (0) | NS |
| Active smoker, | 9 (34.6) | 9 (36) | 7 (26.9) | NS |
| Obesity (BMI > 30 kg/m2), | 3 (11.5) | 0 (0) | 3 (11.5) | NS |
COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, BMI body mass index, NS not significant
* Fisher’s exact test or one-way ANOVA
Fig. 2Accuracy of CRP in outcome prediction. ROC curve of CRP levels in the prediction of hospital mortality. The AUC for a CRP value <169.5 mg/L is 0.716 (0.547–0.886)